Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

Cytokinetics has a 1-year low of $42.72 and a 1-year high of $81.36. The business’s fifty day moving average price is $48.32 and its two-hundred day moving average price is $52.34. Insider ...

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley boosted their FY2024 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, February 5th.

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program, intended ...

Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten ...

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate ...